Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Celularity Inc's Business Segments
Celularity Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 ((Sep 30 2025))
Reportable Segments
6
Largest Segment
Degenerative Disease
Total Revenue
$ 5
Regions Reported
-
Revenue Share by Reportable Segment - Q3 ((Sep 30 2025))
- Degenerative Disease69.7%
- License Royalty and Other55.7%
- Cell Therapy30.1%
- Processing and Storage Fees Net27.4%
- BioBanking27.4%
- Product16.9%
Revenue by Reportable Segment - Q3 ((Sep 30 2025))
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Degenerative Disease | $ 4 | 69.7% |
| License Royalty and Other | $ 3 | 55.7% |
| Cell Therapy | $ 2 | 30.1% |
3 more segments available
Sign in to unlock the full Celularity Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY2025
- Degenerative Disease65.2%
- Biobanking20.5%
- Cell Therapy14.3%
Revenue by Reportable Segment - FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Degenerative Disease | $ 17 | 65.2% |
| Biobanking | $ 5 | 20.5% |
| Cell Therapy | $ 4 | 14.3% |
Revenue by Product & Service Category - FY2025
- Product49.6%
- License Royalty and Other29.9%
- Service20.5%
Revenue by Product & Service Category - FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 13 | 49.6% |
| License Royalty and Other | $ 8 | 29.9% |
| Service | $ 5 | 20.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Celularity Inc
Celularity Inc. is a biotechnology company based in Warren, New Jersey, United States. It was founded in 2017 by Dr. Robert Hariri and Peter Diamandis with a mission to revolutionize the field of regenerative medicine through the development of innovative cellular therapies. The company focuses on harnessing the power of placental cells to create transformative treatments for a variety of diseases, including cancer, infectious diseases, and autoimmune disorders.
The uniqueness of Celularity comes from its proprietary platform technology, which utilizes placental cells obtained from full-term deliveries. These cells possess a remarkable ability to regenerate tissues and modulate immune responses, making them ideal candidates for therapeutic applications. Celularity’s platform technology involves the isolation and characterization of placental cells, including placental hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which can then be expanded in culture to generate large quantities of cells for therapeutic use.
Celularity’s pipeline includes several cellular therapies that are currently in clinical trials or preclinical development. One of its most promising candidates is Cynk-001, an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental HSCs. NK cells are a type of immune cell that can directly kill cancer cells and virally-infected cells without prior sensitization, making them ideal for cancer immunotherapy. Cynk-001 has shown great promise in clinical trials for various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.
In addition to cellular therapies, Celularity’s platform technology has potential applications in other areas. The company has developed a placental-derived extracellular matrix (ECM) product called Axiologik, which has demonstrated the ability to promote tissue repair and regeneration. Axiologik is being evaluated as a potential treatment for chronic wounds, burns, and other tissue injuries.
Celularity Inc. is a privately-held company that has received significant investment from notable biotech investors, including United Therapeutics Corporation, Sorrento Therapeutics, and Dreyfus Health Foundation. The company has also formed strategic partnerships with other industry leaders, such as United Parcel Service (UPS), for the development of logistics and supply chain solutions for the delivery of cellular therapies.
Overall, Celularity Inc. is a cutting-edge biotech company that is at the forefront of the regenerative medicine field. Its innovative use of placental cells and platform technology has the potential to transform the treatment of a variety of diseases and improve patient outcomes.
The uniqueness of Celularity comes from its proprietary platform technology, which utilizes placental cells obtained from full-term deliveries. These cells possess a remarkable ability to regenerate tissues and modulate immune responses, making them ideal candidates for therapeutic applications. Celularity’s platform technology involves the isolation and characterization of placental cells, including placental hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which can then be expanded in culture to generate large quantities of cells for therapeutic use.
Celularity’s pipeline includes several cellular therapies that are currently in clinical trials or preclinical development. One of its most promising candidates is Cynk-001, an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental HSCs. NK cells are a type of immune cell that can directly kill cancer cells and virally-infected cells without prior sensitization, making them ideal for cancer immunotherapy. Cynk-001 has shown great promise in clinical trials for various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.
In addition to cellular therapies, Celularity’s platform technology has potential applications in other areas. The company has developed a placental-derived extracellular matrix (ECM) product called Axiologik, which has demonstrated the ability to promote tissue repair and regeneration. Axiologik is being evaluated as a potential treatment for chronic wounds, burns, and other tissue injuries.
Celularity Inc. is a privately-held company that has received significant investment from notable biotech investors, including United Therapeutics Corporation, Sorrento Therapeutics, and Dreyfus Health Foundation. The company has also formed strategic partnerships with other industry leaders, such as United Parcel Service (UPS), for the development of logistics and supply chain solutions for the delivery of cellular therapies.
Overall, Celularity Inc. is a cutting-edge biotech company that is at the forefront of the regenerative medicine field. Its innovative use of placental cells and platform technology has the potential to transform the treatment of a variety of diseases and improve patient outcomes.
Celularity Inc. is a pioneering biotechnology company focused on harnessing the potential of placental-derived cells to create innovative therapies aimed at treating a wide range of medical conditions. The companys dedication to advancing cellular therapeutics is reflected in its diverse segments, products, and services.
Segments:
1. Cellular Immunotherapy:
Celularitys cellular immunotherapy segment is at the forefront of cancer treatment, emphasizing the development of therapies that bolster the immune systems capacity to identify and destroy malignant cells. Their approach includes harnessing immune cells, particularly natural killer (NK) cells, to directly target and eliminate tumors. The segment aims to develop robust cell-based therapies that not only activate T cells but also modulate the immune response to foster a more effective antitumor environment. Innovations in this space could potentially lead to breakthroughs in treating various cancers, encompassing solid tumors and hematological malignancies.
2. Regenerative Medicine:
The regenerative medicine segment of Celularity is committed to utilizing placental-derived cells for tissue repair, restoration, and regeneration. This area of focus includes developing cutting-edge therapies for a variety of conditions such as chronic wounds, spinal cord injuries, and cardiovascular diseases. The regenerative capabilities of placental cells allow for potential treatments that could promote healing and functional recovery in damaged tissues, offering hope to patients with conditions that are traditionally difficult to treat.
Products:
1. CYNK-001:
CYNK-001 serves as Celularitys flagship product, representing a groundbreaking cell-based immunotherapy generated from NK cells derived from placental tissue. These NK cells have exhibited significant anti-tumor efficacy, positioning CYNK-001 as a promising treatment avenue for multiple cancer types. The therapy is currently undergoing clinical trials to establish its safety and effectiveness across different oncology indications, illustrating Celularitys commitment to advancing cancer treatment options.
2. AOCB-001:
AOCB-001 is an emergent therapy in Celularitys pipeline, utilizing placental mesenchymal stromal cells (PMSCs). This product is aimed at addressing severe respiratory conditions such as acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD). The therapeutic potential of PMSCs lies in their ability to modulate immune responses and promote tissue healing, making AOCB-001 a significant contender for addressing respiratory failure and related complications.
3. Next-Generation CAR-T Therapy:
Celularity is innovating a next-generation CAR-T (chimeric antigen receptor T-cell) therapy that uniquely employs T cells sourced from placental tissue, as opposed to the traditional patient-derived T cells. This innovative approach signifies several advantages, including expedited manufacturing processes, reduced costs, and the potential for more uniformity in the final product. The aim is to enhance patient outcomes by streamlining production while maintaining the therapeutic efficacy associated with CAR-T therapies.
Services:
1. Contract Manufacturing:
Celularity offers state-of-the-art contract manufacturing services aimed at supporting other biotech and pharmaceutical enterprises in their pursuit of cell therapy development. By leveraging their cutting-edge facilities, Celularity can scale the production of clinical-grade cell therapy products, thereby assisting companies in bringing their innovations to market more rapidly and efficiently.
2. Research and Development:
A cornerstone of Celularitys operations is its vigorous research and development initiatives. The company collaborates with both academic institutions and industry partners to explore novel applications for cell-based therapies. This collaborative approach fosters the discovery of innovative treatments that can significantly enhance patient outcomes across various medical conditions.
3. Clinical Trials:
Celularity is actively engaged in conducting clinical trials for multiple indications, including cancer, COVID-19, and wound healing therapies. By prioritizing rigorous clinical research, the company emphasizes the importance of establishing the safety and efficacy of its cell therapies to gain regulatory approvals and ensure that their products meet the highest standards of patient care.
Conclusion:
Celularity Inc. stands out in the biotechnology field by leveraging the immense potential of placental cells, translating scientific innovation into therapeutic applications. The companys diverse segments align with its mission of improving patient outcomes across a spectrum of diseases, thereby underscoring its commitment to advancing modern medicine through pioneering cell therapies.
Segments:
1. Cellular Immunotherapy:
Celularitys cellular immunotherapy segment is at the forefront of cancer treatment, emphasizing the development of therapies that bolster the immune systems capacity to identify and destroy malignant cells. Their approach includes harnessing immune cells, particularly natural killer (NK) cells, to directly target and eliminate tumors. The segment aims to develop robust cell-based therapies that not only activate T cells but also modulate the immune response to foster a more effective antitumor environment. Innovations in this space could potentially lead to breakthroughs in treating various cancers, encompassing solid tumors and hematological malignancies.
2. Regenerative Medicine:
The regenerative medicine segment of Celularity is committed to utilizing placental-derived cells for tissue repair, restoration, and regeneration. This area of focus includes developing cutting-edge therapies for a variety of conditions such as chronic wounds, spinal cord injuries, and cardiovascular diseases. The regenerative capabilities of placental cells allow for potential treatments that could promote healing and functional recovery in damaged tissues, offering hope to patients with conditions that are traditionally difficult to treat.
Products:
1. CYNK-001:
CYNK-001 serves as Celularitys flagship product, representing a groundbreaking cell-based immunotherapy generated from NK cells derived from placental tissue. These NK cells have exhibited significant anti-tumor efficacy, positioning CYNK-001 as a promising treatment avenue for multiple cancer types. The therapy is currently undergoing clinical trials to establish its safety and effectiveness across different oncology indications, illustrating Celularitys commitment to advancing cancer treatment options.
2. AOCB-001:
AOCB-001 is an emergent therapy in Celularitys pipeline, utilizing placental mesenchymal stromal cells (PMSCs). This product is aimed at addressing severe respiratory conditions such as acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD). The therapeutic potential of PMSCs lies in their ability to modulate immune responses and promote tissue healing, making AOCB-001 a significant contender for addressing respiratory failure and related complications.
3. Next-Generation CAR-T Therapy:
Celularity is innovating a next-generation CAR-T (chimeric antigen receptor T-cell) therapy that uniquely employs T cells sourced from placental tissue, as opposed to the traditional patient-derived T cells. This innovative approach signifies several advantages, including expedited manufacturing processes, reduced costs, and the potential for more uniformity in the final product. The aim is to enhance patient outcomes by streamlining production while maintaining the therapeutic efficacy associated with CAR-T therapies.
Services:
1. Contract Manufacturing:
Celularity offers state-of-the-art contract manufacturing services aimed at supporting other biotech and pharmaceutical enterprises in their pursuit of cell therapy development. By leveraging their cutting-edge facilities, Celularity can scale the production of clinical-grade cell therapy products, thereby assisting companies in bringing their innovations to market more rapidly and efficiently.
2. Research and Development:
A cornerstone of Celularitys operations is its vigorous research and development initiatives. The company collaborates with both academic institutions and industry partners to explore novel applications for cell-based therapies. This collaborative approach fosters the discovery of innovative treatments that can significantly enhance patient outcomes across various medical conditions.
3. Clinical Trials:
Celularity is actively engaged in conducting clinical trials for multiple indications, including cancer, COVID-19, and wound healing therapies. By prioritizing rigorous clinical research, the company emphasizes the importance of establishing the safety and efficacy of its cell therapies to gain regulatory approvals and ensure that their products meet the highest standards of patient care.
Conclusion:
Celularity Inc. stands out in the biotechnology field by leveraging the immense potential of placental cells, translating scientific innovation into therapeutic applications. The companys diverse segments align with its mission of improving patient outcomes across a spectrum of diseases, thereby underscoring its commitment to advancing modern medicine through pioneering cell therapies.